Healthcare Industry Type 1 Diabetes (T1D) Market Size | Page 2

Your Catalyst To a Lucrative Business
anticipated to increase. The reason being the quick action and optimum performance of these two over long -
acting insulin.
The insulin analogs market is consolidated in nature as three companies account for more than 50% of the total
market share. The reason being extensive product offerings and continuous research and development
activities. This market is witnessing an ongoing patent erosion affecting the market sustainability of companies.
Also, high probability of launch of several biosimilars by new entrants, major players might face competition
during the forecast period.
To enhance the overall sustainability, established players such as Novo Nordisk, Sanofi, and Eli Lilly are
continuously investing in the development of the improved versions of insulin products. For instance, recent
launches by Novo Nordisk (Xultophy, Tresiba) and Sanofi's Toujeo (improved version of Lantus). These factors
exhibit the promising growth for type 1 diabetes treatment market.
Details of Report @ https://www.hexaresearch.com/research-report/type-1-diabetes-t1d-market
Hexa Research has segmented the global type 1 diabetes (T1D) market based on insulin analog, and region:
Segmentation by insulin analog, 2014 - 2024 (USD Million)
• Rapid acting
• Long acting
• Premix analogs
Segmentation by region, 2014 - 2024 (USD Million)
• North America
• U.S.
• Europe
• UK
• Asia Pacific
• China
• India
• Rest of the world
Key players analyzed
• ADOCIA
• Biocon
• Bioton
• Eli Lilly and Company
• Novo Nordisk
• Sanofi
• Wockhardt
Browse Related Category Market Reports @ https://www.hexaresearch.com/research-
category/pharmaceuticals-industry
Follow Us: